We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $235M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 14

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

6% more funds holding

Funds holding: 7883 (+5)

7% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.41M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

8% less capital invested

Capital invested by funds: $257M → $235M (-$21.5M)

Holders
83
Holders Change
+5
Holders Change %
+6.41%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
44
Reduced
14
Closed
8
Calls
$1.51M
Puts
$1.41M
Net Calls
+$97K
Net Calls Change
-$103K

OMED Hedge Fund Activity: Q2 2015 in Review

83 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2015, worth a combined $235M — down 8.4% from $257M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new OMED positions and 8 closed out — a net gain of 5 holders — while 44 added to existing stakes and 14 trimmed.

The largest buyer was Cannell & Co, adding an estimated $3.36M. The largest seller was Sectoral Asset Management, cutting an estimated $4.05M.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2015, up from 78 in Q1 2015.
  • Funds reported $235M of OncoMed Pharmaceuticals, Inc. stock for Q2 2015, down 8.4% quarter-over-quarter.
  • 13 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2015 and 8 closed out, a net change of +5 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2015 was Cannell & Co, an estimated $3.36M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2015 was Sectoral Asset Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q2 2015.